SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is facing high volatility as investors speculate on the timing of the 80th clinical event, with the community actively debating whether the current price pullback is a healthy consolidation driven by warrant exercises and profit-taking or a sign of deeper fundamental issues. Long-term bulls remain focused on the upcoming REGAL Phase 3 data, while vocal dissenters continue to challenge the company's clinical history and transparency.

NIO, Inc. operates as a holding company, which engages in the design, development, manufacture, and sale of smart electric vehicles. It offers its products under the brands NIO, ONVO, and FIREFLY. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Shanghai, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the market reacts to strong quarterly financial results, including an earnings beat and bullish delivery guidance, which have fueled ongoing community debate over potential stock manipulation. Investors remain sharply divided between those viewing the current share price as a deep-value accumulation opportunity and those frustrated by persistent price volatility despite the company's improving fundamentals.

Applied Digital Corporation

Applied Digital is surging after announcing a significant 15-year hyperscaler lease for its fourth AI campus, fueling community excitement over a growing multibillion-dollar backlog and rising analyst price targets. Shareholders are actively debating the potential for an imminent short squeeze and expressing high conviction in the firm's long-term infrastructure strategy.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending following a proposed $100 million equity-backed investment from the U.S. government, sparking intense debate between bulls citing national strategic importance and bears pointing to fundamental concerns regarding low revenue and share dilution. The community remains deeply divided, with active discussion focusing on whether this government endorsement signals a long-term sector mandate or merely a volatile momentum play for speculative traders.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is experiencing extreme volatility as investors digest a combination of robust growth in its AGI CPU pipeline and concerns over supply constraints that capped near-term expectations. The community remains deeply divided, with many traders debating whether current price swings represent a healthy consolidation for a long-term AI infrastructure play or the bursting of a valuation bubble.

Intuit, Inc. engages in the provision of business and financial management solutions. It operates through the following segments: Small Business and Self-Employed, Consumer, Credit Karma, and ProTax. The Small Business and Self-Employed segment offers QuickBooks financial and business management online services and desktop software, payroll solutions, payment processing solutions, and financing for small businesses. The Consumer segment includes do-it-yourself and assisted TurboTax income tax preparation products and services. The Credit Karma segment serves consumers with a personal finance platform that provides personalized recommendations of credit cards, home, auto and personal loans, and insurance products, and online savings and checking accounts. The ProTax segment refers to the professional accountants in the U.S. and Canada, who are essential to both small business success and tax preparation and filing. The company was founded by Scott D. Cook and Thomas A. Proulx in March 1983 and is headquartered in Mountain View, CA.

Intuit Inc

Intuit shares are facing intense selling pressure following a double-beat earnings report, as investors focus on a 17% workforce reduction and concerns regarding competitive pricing headwinds. The community is sharply divided between those viewing the decline as a major buying opportunity due to strong fundamentals and share buybacks, and those fearing structural disruption from AI alternatives impacting the company's core tax software business.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is seeing massive momentum and extreme trading volume following news that the company secured a significant letter of intent for government funding to accelerate its neutral-atom quantum technology. The community is actively debating the company's valuation relative to its peers and the long-term strategic validation provided by federal equity stakes.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is generating intense debate as it pivots toward AI data center infrastructure through its new solid-state transformer technology, even as the stock faces downward pressure from ongoing challenges in the residential solar sector. While retail investors remain divided between viewing the move as a major long-term re-rating catalyst and concerns over persistent fundamental headwinds, high short interest has turned the ticker into a volatile battleground for active traders.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing (RGTI) is trending following a massive industry-wide rally triggered by reports of a multi-billion dollar U.S. government investment initiative in quantum technology. The community is sharply divided, with bulls pointing to the long-term strategic validation of the sector, while bears criticize the speculative valuations and high cash burn of these companies.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is currently trading near historical highs as investors lean into the stock as a defensive "safe haven" amidst broader market volatility and inflationary pressures. While the company faces intense scrutiny over its high valuation multiples, the community remains actively divided between those betting on continued growth through retail dominance and those expecting a significant pullback due to stretched fundamentals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Leerink said recent stock weakness tied to a competitor downgrade and board departures has created a buying opportunity ahead of key pancreatic cancer data expected later this year.</li><li>Mizuho raised its price target for TNGX to $30 from $20 and maintained an ‘Outperform’ rating, citing stronger front-line pancreatic cancer revenue expectations.</li><li>Wedbush raised its price target on Tango Therapeutics to $33 from $19 and maintained an ‘Outperform’ rating, citing recent financing activity and progress in vopimetostat development.</li></ul>Shares of Tango Therapeutics Inc. (TNGX) lost more than a fifth of their value on Friday after the company reported revenue of $0 in the first quarter, missing Wall Street expectations.Despite the first-quarter (Q1) miss, analysts at Leerink nearly doubled their price target for TNGX stock on Friday, according to TheFly.At the time of writing,&nbsp;<a href="https://stocktwits.com/symbol/TNGX">Tango Therapeutics shares</a> were headed for their worst single-day fall in more than 19 months.<h2 class="st-heading-2">Leerink, Mizuho, Wedbush Turn Bullish On TNGX</h2>Leerink raised its price target on Tango Therapeutics to $55 from $28, implying an upside potential of 184% from current levels, while maintaining its ‘Outperform’ rating after the company’s Q1 results and pipeline update.The firm said recent stock weakness tied to a competitor downgrade and board departures has created a buying opportunity ahead of key pancreatic cancer data expected later this year.Leerink also backed Tango’s decision to prioritize first-line pancreatic cancer studies combining vopimetostat with RAS(ON) inhibitors over a standalone second-line trial.Analysts at Mizuho raised their price target on Tango Therapeutics to $30 from $20, while keeping an ‘Outperform’ rating. The firm cited increased front-line pancreatic ductal adenocarcinoma revenue assumptions for the target boost.Wedbush raised its price target on Tango Therapeutics to $33 from $19 and maintained an ‘Outperform’ rating. The analysts cited the company’s recent financing activity and progress in the development of vopimetostat.However, analysts at Piper Sandler downgraded TNGX stock to ‘Neutral’ from ‘Overweight’, but hiked the price target to $24 from $16. The firm stated that it has become less confident in vopimetostat following the company’s shift away from its previously disclosed monotherapy strategy.<h2 class="st-heading-2">TNGX Q1 At A Glance</h2>Tango Therapeutics reported adjusted loss per share of $0.32 in Q1, compared to a loss of $0.36 per share during the same period a year ago. Revenue was nil for the quarter, compared with $5.4 million in the year-ago period.Wall Street expected Tango Therapeutics to report a loss of $0.31 per share on revenue of $0.58 million, according to Fiscal.ai data.The company stated that it had recognized all remaining deferred revenue tied to upfront and research option-extension payments under its Gilead collaboration in fiscal year 2025, after the agreement was terminated and all research activities had concluded.<h2 class="st-heading-2">TNGX Provides Update On Upcoming Milestones</h2>The company expects to report initial Phase 1/2 safety and efficacy data in 2026 for vopimetostat combination trials with daraxonrasib and Revolution Medicines’ zoldonrasib.It also plans to provide a lung cancer update from its vopimetostat monotherapy study this year, along with the release of early Phase 1/2 data from the TNG456 monotherapy trial this year.Additionally, the company aims to begin a Phase 1/2 combination study of vopimetostat and Erasca’s ERAS-0015 in the second half of 2026.<h2 class="st-heading-2">How Did Retail Traders React To TNGX?</h2>Retail sentiment on Stocktwits around Tango Therapeutics trended in the ‘bullish’ territory with message volumes at ‘high’ levels at the time of writing.<a href="https://stocktwits.com/symbol/TNGX">TNGX stock</a> is up 120% year-to-date and 1,182% over the past 12 months. The iShares Russell 2000 ETF (IWM) is up 34% over the past 12 months, while the S&amp;P Biotech ETF (XBI) is up 68%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apollo-torsten-slok-inflation-very-serious-fed-rate-hike-kevin-warsh-powell/cZXmcm4RekG">Apollo’s Torsten Slok Warns Inflation Has Become A ‘Very Serious’ Problem — Says Markets Now Expect Fed Rate Hikes</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Tango Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside

Shares of Tango Therapeutics Inc. (TNGX) lost more than a fifth of their value on Friday after the company reported revenue of $0 in the first quarter, missing Wall Street expectations.

Equity

Leerink raised its price target on Tango Therapeutics to $55 from $28, implying an upside potential of 184% from current levels, while maintaining its ‘Outperform’ rating.

Stifel Remains Bullish on Tango Therapeutics (TNGX)

Stifel Remains Bullish on Tango Therapeutics (TNGX...

RVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense View

Revolution Medicines posts a wider Q1 loss and raises its 2026 expense outlook as R&D and commercial prep costs climb.

Adam Crystal Sells 27,000 Shares of Tango Therapeutics (NASDAQ:TNGX) Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) insider Adam Crystal sold 27,000 shares of Tango Therapeutics stock in a transaction that occurred on Friday, May 1st. The shares were sold at...

Tango Therapeutics (NASDAQ:TNGX) Stock Price Up 7.1% - Time to Buy?

Tango Therapeutics (NASDAQ:TNGX) Trading Up 7.1% - Here's Why...

Tango Therapeutics (TNGX) Expected to Announce Quarterly Earnings on Monday

Tango Therapeutics (NASDAQ:TNGX) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-tango-therapeutics-inc-stock...

Tango Therapeutics (NASDAQ:TNGX) Trading Down 9.7% - Here's What Happened

Tango Therapeutics (NASDAQ:TNGX) Stock Price Down 9.7% - What's Next...

Stifel Nicolaus Issues Positive Forecast for Tango Therapeutics (NASDAQ:TNGX) Stock Price

Stifel Nicolaus increased their price target on shares of Tango Therapeutics from $24.00 to $40.00 and gave the company a "buy" rating in a report on Monday...

Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of "Moderate Buy" by Brokerages

Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) has earned an average rating of "Moderate Buy" from the twelve research firms that are covering the firm, Marketbeat.com reports. One equities...

354,192 Shares in Tango Therapeutics, Inc. $TNGX Bought by Mass General Brigham Inc

Mass General Brigham Inc acquired a new position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing...

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.

TNGX
Tango Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest TNGX News

TNGXTango Therapeutics Inc